title: Gene therapy of coronary artery disease with phvegf165--early outcome.
abstract: BACKGROUND
  Gene therapy is a new, experimental method of treatment in patients with coronary artery disease (CAD).
  
  
  OBJECTIVE
  To determine the safety and efficacy of gene encoding vascular endothelial growth factor (VEGF165) administered directly into the myocardium as the single treatment or combined with coronary artery by-pass grafting (CABG).
  
  
  METHODS
  VEGF gene transfer was performed in 22 patients (20 male, 2 female, ages from 48 to 73 years old). A 200 micro g of the plasmid encoding VEGF165 was injected into the ischaemic myocardium which could not be surgically revascularised in patients undergoing CABG (n=14), and 400 micro g - in patients without CABG (n=8). The value of ejection fraction (EF), myocardial perfusion, angiogram, ventriculography, and nitroglycerine consumption as well as quality of life were evaluated pre- and postoperatively.
  
  
  RESULTS
  The majority of patients had no complications and no fatal outcome was observed. Two patients developed acute myocardial infarction. Left ventricular function values improved and the majority of patients were free from angina 6 months after surgery. Patients reported improved quality of life and a reduction in nitroglycerine usage. A reduction in the ischaemic defects detected by SPECT was also observed. In some patients angiography revealed improved collateral filling.
  
  
  CONCLUSIONS
  Direct myocardial administration of genes encoding VEGF165 can be an effective method of treatment in patients with chronic and advanced CAD either as a supplementary treatment or as a single therapy.
authors.affiliation: 2nd Cardiac Surgery Dept., Institute of Cardiology, Warsaw, Poland.
authors.forename: Piotr
authors.initials: P
authors.lastname: Kołsut
authors.forename: Maciej
authors.initials: M
authors.lastname: Małecki
authors.forename: Piotr
authors.initials: P
authors.lastname: Zelazny
authors.forename: Anna
authors.initials: A
authors.lastname: Teresińska
authors.forename: Bohdan
authors.initials: B
authors.lastname: Firek
authors.forename: Przemysław
authors.initials: P
authors.lastname: Janik
authors.forename: Zbigniew
authors.initials: Z
authors.lastname: Religa
mesh_terms: D000368:Aged; D017023:Coronary Angiography; D001026:Coronary Artery Bypass; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy*; D003326:Coronary Circulation; D005260:Female; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D008297:Male; D008875:Middle Aged; D005996:Nitroglycerin / Q000008:administration & dosage; D011788:Quality of Life; D013318:Stroke Volume; D015899:Tomography, Emission-Computed, Single-Photon; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000008:administration & dosage* / Q000235:genetics
chemical_list: C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D005996:Nitroglycerin